New oral anticoagulants: key messages for clinicians

Submitted: 9 December 2013
Accepted: 9 December 2013
Published: 24 December 2013
Abstract Views: 1175
PDF: 817
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

New oral anticoagulants are an effective and safe alternative to vitamin K antagonists in many fields of clinical practice. The use of the direct inhibitors of activated Factor II (dabigatran) and activated Factor X (apixaban and rivaroxaban), both in patients with non-valvular atrial fibrillation (NVAF) and those with acute venous thromboembolism (VTE), is of great interest for internal medicine physicians. This paper aims to give practical guidance on management (starting therapy, follow up and bleeding complications) of patients treated with dabigatran, rivaroxaban or apixaban for NVAF or acute VTE providing practical tables concerning the phases of therapy, management of complications, drug interaction and dose adjustment if renal impairment occurs.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Giorgi-Pierfranceschi, M., Cattabiani, C., & Dentali, F. (2013). New oral anticoagulants: key messages for clinicians. Italian Journal of Medicine, 7(s8), 74–84. https://doi.org/10.4081/itjm.2013.s8.74

Similar Articles

You may also start an advanced similarity search for this article.